Latest & greatest articles for nivolumab

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on nivolumab or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on nivolumab and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for nivolumab

41. The efficacy of nivolumab as a checkpoint inhibitor drug on the survival rate of patients with Hodgkin cancer: a meta-analysis of prospective clinical studies

The efficacy of nivolumab as a checkpoint inhibitor drug on the survival rate of patients with Hodgkin cancer: a meta-analysis of prospective clinical studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2018 PROSPERO

42. The effectiveness of nivolumab in treating malignant melanoma: a systematic review and meta-analysis

The effectiveness of nivolumab in treating malignant melanoma: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2018 PROSPERO

43. Nivolumab vs Docetaxel as second or third line therapy for advanced/recurrent non-small cell lung cancer: A systematic review and meta-analysis

Nivolumab vs Docetaxel as second or third line therapy for advanced/recurrent non-small cell lung cancer: A systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

44. The different benefits and side effects of nivolumab combined with ipilimumab in diverse cancer: a systematic review and meta-analysis protocol

The different benefits and side effects of nivolumab combined with ipilimumab in diverse cancer: a systematic review and meta-analysis protocol Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2018 PROSPERO

45. Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)

Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision) Extract 1 Translation of the executive summary of the dossier assessment Nivolumab (Melanom) – Nutzenbewertung gemäß § 35a SGB V (Ablauf Befristung) (Version 1.0; Status: 13 September 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative (...) and legally binding. IQWiG Reports – Commission No. A18-40 Nivolumab (melanoma) – Benefit assessment according to §35a Social Code Book V 1 (expiry of the decision) Extract of dossier assessment A18-40 Version 1.0 Nivolumab (melanoma) 13 September 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Nivolumab (melanoma) – Benefit assessment according to §35a Social Code Book V Commissioning agency

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

46. Nivolumab (Opdivo) for urothelial carcinoma

Nivolumab (Opdivo) for urothelial carcinoma 1 Cost-effectiveness of nivolumab (Opdivo®) for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum- containing chemotherapy The NCPE has issued a recommendation regarding the cost-effectiveness of nivolumab (Opdivo®). Following assessment of the Applicant’s submission, the NCPE recommends that nivolumab (Opdivo®) not be considered for reimbursement. This recommendation should (...) be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013. The HSE asked the National Centre for Pharmacoeconomics (NCPE) to carry out an assessment of the applicant’s (BMS) economic dossier on the cost effectiveness of nivolumab (Opdivo®). The NCPE uses a decision framework to systematically assess whether a technology is cost-effective. This includes clinical effectiveness and health related quality of life benefits, which the new

2018 Pediatric Endocrine Society

47. Nivolumab (classical Hodgkin lymphoma) - Addendum to Commission A16-76

Nivolumab (classical Hodgkin lymphoma) - Addendum to Commission A16-76 1 Translation of addendum A17-21 Nivolumab (klassisches Hodgkin-Lymphom) – Addendum zum Auftrag A16-76 (Version 1.0; Status: 24 May 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 24 May 2017 1.0 Commission: A17-21 Version: Status: IQWiG Reports – Commission No. A17-21 (...) Nivolumab (classical Hodgkin lymphoma) – Addendum to Commission A16-76 1 Addendum A17-21 Version 1.0 Nivolumab – Addendum to Commission A16-76 24 May 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Nivolumab (classical Hodgkin lymphoma) – Addendum to Commission A16-76 Commissioning agency: Federal Joint Committee Commission awarded on: 11 May 2017 Internal Commission No.: A17-21 Address

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

48. Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy

Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy Niv Nivolumab for treating squamous cell olumab for treating squamous cell carcinoma of the head and neck after carcinoma of the head and neck after platinum-based chemother platinum-based chemotherap apy y T echnology appraisal guidance Published: 22 November 2017 nice.org.uk/guidance/ta490 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms (...) due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (TA490) © NICE 2019. All rights reserved

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

49. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057) Full Text available with Trip Pro

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057) Purpose Nivolumab, a programmed death-1 inhibitor, prolonged overall survival compared with docetaxel in two independent phase III studies in previously treated patients with advanced squamous (CheckMate 017; ClinicalTrials.gov identifier: NCT01642004) or nonsquamous (CheckMate 057 (...) ; ClinicalTrials.gov identifier: NCT01673867) non-small-cell lung cancer (NSCLC). We report updated results, including a pooled analysis of the two studies. Methods Patients with stage IIIB/IV squamous (N = 272) or nonsquamous (N = 582) NSCLC and disease progression during or after prior platinum-based chemotherapy were randomly assigned 1:1 to nivolumab (3 mg/kg every 2 weeks) or docetaxel (75 mg/m2 every 3 weeks). Minimum follow-up for survival was 24.2 months. Results Two-year overall survival rates

2017 EvidenceUpdates

50. Pulmonary pleomorphic carcinoma with few PD‐1‐positive immune cells and regulatory T cells that showed a complete response to nivolumab Full Text available with Trip Pro

Pulmonary pleomorphic carcinoma with few PD‐1‐positive immune cells and regulatory T cells that showed a complete response to nivolumab Pulmonary pleomorphic carcinoma has been shown to respond remarkably to PD-1 inhibitors; however, the biomarkers for this therapy have not been fully proven. We report a case of pulmonary pleomorphic carcinoma with overexpressed PD-L1, in which a complete response to nivolumab was sustained for >14 months. Immunohistochemical analysis revealed few PD-1

2017 Thoracic cancer

51. Nivolumab for previously treated squamous non-small-cell lung cancer

Nivolumab for previously treated squamous non-small-cell lung cancer Niv Nivolumab for pre olumab for previously treated viously treated squamous non-small-cell lung cancer squamous non-small-cell lung cancer T echnology appraisal guidance Published: 1 November 2017 nice.org.uk/guidance/ta483 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance (...) inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Nivolumab for previously treated squamous non-small-cell lung cancer (TA483) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 32Contents Contents 1 Recommendations 4 2 The technology

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

52. Nivolumab for previously treated non-squamous non-small-cell lung cancer

Nivolumab for previously treated non-squamous non-small-cell lung cancer Niv Nivolumab for pre olumab for previously treated non- viously treated non- squamous non-small-cell lung cancer squamous non-small-cell lung cancer T echnology appraisal guidance Published: 1 November 2017 nice.org.uk/guidance/ta484 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations (...) and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Nivolumab for previously treated non-squamous non-small-cell lung cancer (TA484) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 34Contents Contents 1

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

53. Nivolumab (Opdivo) in combination with platinum

Nivolumab (Opdivo) in combination with platinum Nivolumab (Opdivo) in combination with platinum | Innovation Observatory toggle menu Menu Search View All Filter by Speciality Filter by Year Filter by Category This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our (...) stakeholders. > > > Nivolumab (Opdivo) in combination with platinum Nivolumab (Opdivo) in combination with platinum October 2017 Nivolumab is an intravenous drug under development for the management of advanced (Stage IV) NSCLC. The drug acts on specific proteins (receptors) on immune cells, allowing the defence system of the body to decrease the growth of cancer cells. If licensed, Nivolumab in combination with the current standard of care (platinum doublet chemotherapy) may offer an additional treatment

2017 NIHR Innovation Observatory

54. Afatinib treatment of a squamous lung cancer after tumor progression of nivolumab Full Text available with Trip Pro

Afatinib treatment of a squamous lung cancer after tumor progression of nivolumab Nivolumab prolonged disease control in a patient with advanced squamous lung cancer that was refractory to multiple treatments. The rapid eradication of cancer after the administration of nivolumab caused hemoptysis and repeated infection. Six months after immunotherapy, mediastinal lymph node metastasis developed and afatinib effectively relieved dysphonia associated with nerve paralysis.© 2017 The Authors

2017 Thoracic cancer

55. Nivolumab-induced hypothyroidism and selective pituitary insufficiency in a patient with lung adenocarcinoma: a case report and review of the literature Full Text available with Trip Pro

Nivolumab-induced hypothyroidism and selective pituitary insufficiency in a patient with lung adenocarcinoma: a case report and review of the literature Immune checkpoint blockade including programmed cell death 1 pathway inhibition with agents such as nivolumab is gaining ground in a wide array of malignancies, so far demonstrating significantly improved survival rates even in metastatic, often multiply pretreated settings. Although targeted in nature and generally well-tolerated compared (...) with conventional anticancer treatments, these agents are often linked to a newly emerged group of adverse reactions, referred to as immune-related adverse events, which can also affect endocrine organs. This is a case report of a patient who received nivolumab for the treatment of recurrent metastatic non-small cell lung cancer and developed primary hypothyroidism and secondary adrenal insufficiency caused by selective pituitary dysfunction (with preservation of all other endocrine functions). After hormone

2017 ESMO open

56. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. (Abstract)

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, two or more previous regimens of chemotherapy have a poor prognosis, and current guidelines do not recommend any specific treatments (...) for these patients. We assessed the efficacy and safety of nivolumab, a fully human IgG4 monoclonal antibody inhibitor of programmed death-1 (PD-1), in patients with advanced gastric or gastro-oesophageal junction cancer who had been previously been treated with two or more chemotherapy regimens.In this randomised, double-blind, placebo-controlled, phase 3 trial done at 49 clinical sites in Japan, South Korea, and Taiwan, eligible patients (aged ≥20 years with unresectable advanced or recurrent gastric or gastro

2017 Lancet Controlled trial quality: predicted high

57. [Nivolumab (squamous cell carcinoma of the head and neck) - benefit assessment according to õ35a Social Code Book V]

[Nivolumab (squamous cell carcinoma of the head and neck) - benefit assessment according to õ35a Social Code Book V] Nivolumab (Plattenepithelkarzinom des Kopf-Hals-Bereichs): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung [Nivolumab (squamous cell carcinoma of the head and neck) - benefit assessment according to §35a Social Code Book V] Nivolumab (Plattenepithelkarzinom des Kopf-Hals-Bereichs): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung [Nivolumab (squamous cell carcinoma (...) of the head and neck) - benefit assessment according to §35a Social Code Book V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Nivolumab (Plattenepithelkarzinom des Kopf-Hals-Bereichs): Nutzenbewertung gemäß § 35a SGB

2017 Health Technology Assessment (HTA) Database.

58. Nivolumab (Opdivo) with ipilimumab (Yervoy) for recurrent, metastatic, squamous cell head and neck cancer – first line

Nivolumab (Opdivo) with ipilimumab (Yervoy) for recurrent, metastatic, squamous cell head and neck cancer – first line Nivolumab (Opdivo) with ipilimumab (Yervoy) for recurrent, metastatic, squamous cell head and neck cancer – first line | Innovation Observatory toggle menu Menu Search View All Filter by Speciality Filter by Year Filter by Category This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed (...) technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders. > > > Nivolumab (Opdivo) with ipilimumab (Yervoy) for recurrent, metastatic, squamous cell head and neck cancer – first line Nivolumab (Opdivo) with ipilimumab (Yervoy) for recurrent, metastatic, squamous cell head and neck cancer – first line September 2017 Nivolumab is a type of protein designed to attach to a certain type of white blood cells called the T

2017 NIHR Innovation Observatory

59. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. Full Text available with Trip Pro

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. Nivolumab combined with ipilimumab resulted in longer progression-free survival and a higher objective response rate than ipilimumab alone in a phase 3 trial involving patients with advanced melanoma. We now report 3-year overall survival outcomes in this trial.We randomly assigned, in a 1:1:1 ratio, patients with previously untreated advanced melanoma to receive nivolumab at a dose of 1 mg per kilogram of body weight (...) plus ipilimumab at a dose of 3 mg per kilogram every 3 weeks for four doses, followed by nivolumab at a dose of 3 mg per kilogram every 2 weeks; nivolumab at a dose of 3 mg per kilogram every 2 weeks plus placebo; or ipilimumab at a dose of 3 mg per kilogram every 3 weeks for four doses plus placebo, until progression, the occurrence of unacceptable toxic effects, or withdrawal of consent. Randomization was stratified according to programmed death ligand 1 (PD-L1) status, BRAF mutation status

2017 NEJM Controlled trial quality: predicted high

60. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. Full Text available with Trip Pro

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. Nivolumab and ipilimumab are immune checkpoint inhibitors that have been approved for the treatment of advanced melanoma. In the United States, ipilimumab has also been approved as adjuvant therapy for melanoma on the basis of recurrence-free and overall survival rates that were higher than those with placebo in a phase 3 trial. We wanted to determine the efficacy of nivolumab versus ipilimumab for adjuvant therapy (...) in patients with resected advanced melanoma.In this randomized, double-blind, phase 3 trial, we randomly assigned 906 patients (≥15 years of age) who were undergoing complete resection of stage IIIB, IIIC, or IV melanoma to receive an intravenous infusion of either nivolumab at a dose of 3 mg per kilogram of body weight every 2 weeks (453 patients) or ipilimumab at a dose of 10 mg per kilogram every 3 weeks for four doses and then every 12 weeks (453 patients). The patients were treated for a period of up

2017 NEJM Controlled trial quality: predicted high